Suchergebnisse - "Jin, Jin Yan"

PubPharm (47)

1

Applying interpretable machine learning workflow to evaluate exposure-response relationships for large-molecule oncology drugs

enthalten in: CPT: pharmacometrics & systems pharmacology | 2022

von Liu, G. | Lu, J. | Lim, H. | +2

2

Applying interpretable machine learning workflow to evaluate exposure–response relationships for large‐molecule oncology drugs

enthalten in: CPT: Pharmacometrics & Systems Pharmacology | 2022

von Liu, G. | Lu, J. | Lim, H. | +2

3

Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma

enthalten in: Leukemia & lymphoma | 2020

von Lu, T. | Gibiansky, L. | Li, X. | +9

4

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

enthalten in: Pharmaceutical research | 2020

von Lu, D. | Lu, T. | Shi, R. | +11

5

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

enthalten in: Pharmaceutical research | 2020

von Lu, D. | Lu, T. | Shi, R. | +11

6

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

enthalten in: Pharmaceutical research | 2020

von Lu, D. | Lu, T. | Shi, R. | +11

7

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

enthalten in: Pharmaceutical research | 2020

von Lu, D. | Lu, T. | Shi, R. | +11

8

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

enthalten in: Cancer chemotherapy and pharmacology | 2020

von Shi, R. | Lu, T. | Ku, G. | +10

9

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

enthalten in: Cancer chemotherapy and pharmacology | 2020

von Shi, R. | Lu, T. | Ku, G. | +10

10

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

enthalten in: Cancer chemotherapy and pharmacology | 2020

von Shi, R. | Lu, T. | Ku, G. | +10

1
2
3
4
5
Nächster »
[5]